Skip to main content

Table 1 Baseline characteristics of the patients and the associations between patient characteristics and ANCA status at switching to maintenance therapy. p refers to the difference between the ANCA +ve and ANCA-ve status at switch to maintenance therapy.

From: Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse

  All patients ANCA –ve ANCA + ve p
n (%) 252 141 (56%) 111 (44%) 0.36
 Male
 Female
158
94
92
49
66
45
Age (years) 59 (47–67) 62 (50–68) 54 (42–66) 0.009
Creatinine at entry (μmol/L) 177 (108–239) 185 (126–327) 151 (97–258) 0.007
Creatinine strata (μmol/L)     0.077
  < 100
 101–200
  > 200
54
90
108
24
49
68
30
41
40
ANCA specificity at entry     0.7
 MPO
 PR3
107
145
58
83
49
62
Diagnosis     0.45
 MPA
 GPA
118
134
63
78
55
56
Time to remission (months) 3 (2.7–4.1) 3 (2–3.7) 3.2 (3–4.5) 0.001
Cyclophosphamide     0.53
 Continuous
 Pulse
117
135
68
73
49
62
Maintenance therapy     0.093
 AZA
 MMF
 Other
175
73
4
103
34
4
72
39
0
Relapse:no-relapse 102:150 47:94 55:56 0.025
  1. ANCA anti-neutrophil cytoplasm antibodies, AZA azathioprine, GPA granulomatosis with polyangiitis, MMF mycophenolate mofetil, MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase 3